Stryker announces leadership succession
Stryker (NYSE:SYK) has announced a planned leadership transition, effective January 1, 2027. Kevin Lobo will move from CEO to Executive Chair of the Board of Directors, and current President and COO Spencer Stiles will succeed him as Chief Executive Officer and join the Board. This succession follows Lobo's 14-year tenure as CEO, during which he significantly grew the company, and Stiles' nearly three decades of leadership across various Stryker businesses.
Stryker stock after-hours at EUR 253.75: plus 3.61 percent versus prior close
Stryker stock traded at EUR 253.75 after-hours on October 5, 2026, marking a 3.61 percent increase from its prior close. The company also announced the launch of its Mako 4 SmartRobotics platform in India. This fourth-generation Mako system aims to enhance surgical planning and execution for various joint replacement procedures.
Stryker Corp Stock (SYK) Moved Up by 3.32% on Oct 5: Facts Behind the Movement
Stryker Corp (SYK) saw its stock rise by 3.32% on October 5, driven by bargain hunting after a September sell-off and positive analyst commentary. Despite temporary supply chain and manufacturing disruptions in its Peripheral Vascular unit, the company's core business segments remain strong with solid organic sales growth. Investors are now focused on the upcoming third-quarter earnings for updates on supply chain resolution and margin progression.
Stryker upgraded to 'Strong Buy' after price drop to $275, showing strong growth and solid returns potential.
Stryker (SYK) has been upgraded to a 'Strong Buy' following a price drop to $275, which analysts believe presents an attractive valuation. The company is experiencing robust organic sales growth across multiple segments, fueled by strong demand and high equipment backlogs, particularly in Mako robotic-assisted procedures and ambulatory surgery centers. Despite recent dips related to manufacturing issues, Stryker maintains a strong balance sheet and dividend aristocrat status, positioning it for potential double-digit EPS growth and mid to high-teens annual total returns.
Stryker: This Dividend Aristocrat Is Finally Cheap Again (NYSE:SYK)
Stryker (SYK) has been upgraded to 'Strong Buy' following a significant price pullback, making it an attractive investment. The company demonstrates strong organic sales growth across its segments and geographies, driven by innovations like Mako robotic-assisted procedures and ASC expansion. With a solid balance sheet, Dividend Aristocrat status, and resilient demand, Stryker is positioned for double-digit EPS growth and mid to high-teens annual total returns.
Stryker Launches Mako 4 SmartRobotics™ in India, Advancing the Next Generation of Robotic-Assisted Joint Replacement
Stryker has launched Mako 4 SmartRobotics™ in India, marking the fourth generation of its robotic-arm assisted technology for joint replacement. This new system offers patient-specific planning, robotic technology, and haptic guidance for total knee, partial knee, and total hip procedures. The launch aims to meet the growing demand for advanced treatments in India and build on the Mako platform's global success with over 2.5 million procedures performed across 47 countries.
Stryker Launches Mako 4 SmartRobotics™ in India, Advancing the Next Generation of Robotic-Assisted Joint Replacement
Stryker has launched Mako 4 SmartRobotics™ in India, introducing its latest robotic-arm assisted technology for joint replacement. This fourth generation Mako system offers patient-specific planning, robotic assistance, and haptic guidance for total knee, partial knee, and total hip procedures. The launch aims to improve surgical precision and expand access to advanced joint replacement care across India, building on the global success of the Mako platform.
Stryker stock enters October with a Q3 results date set
Stryker Corporation's stock was last traded at USD 275.43 on October 2, 2026, with Q3 results scheduled for release on October 29, 2026. The company reported strong Q2 2026 revenue of USD 6.59 billion and adjusted EPS of USD 3.69, despite a Peripheral Vascular supply disruption. Analysts maintain a "Moderate Buy" consensus for the stock, with an average twelve-month price target of USD 372.64.
Intuitive Surgical Inc. Research & Ratings | ISRG
This article provides a detailed research and ratings overview for Intuitive Surgical Inc. (ISRG), including analyst ratings, price targets, stock grader information, company financials, and earnings estimates. It shows a consensus "Buy" rating with an average price target of $479.86 and details upcoming earnings reports.
Intuitive Surgical Inc. Stock Grades | ISRG
This article provides detailed stock information for Intuitive Surgical Inc. (ISRG), including its current stock grade, analyst ratings, key financial metrics, and company overview. It highlights an average price target of $479.86 from 35 ratings and notes the company's P/E Ratio (TTM) of 44.92. The company specializes in robotic-assisted surgical solutions.
Stryker stock faces a rating split before October 29 results
Stryker stock is experiencing a split in analyst ratings ahead of its third-quarter results webcast on October 29, 2026. While Wall Street Zen downgraded Stryker from Buy to Hold, RBC Capital maintained a Buy rating with a USD 420.00 price target. The company's second-quarter revenue of USD 6.59 billion exceeded consensus, and the stock is currently trading near its 52-week low.
Securities firm investigates Stryker for possib...
A securities firm is investigating Stryker Corporation for potentially misleading investors about ongoing manufacturing issues in its peripheral vascular business. The investigation follows a significant stock drop after the CFO revealed a problem, which the CEO had previously claimed was resolved, was still persisting. Investors who suffered losses are encouraged to contact the firm.
Bicycle Therapeutics Plc ADR (BCYC-Q) Stock Price and News
This article provides stock price information and recent news for Bicycle Therapeutics Plc ADR (BCYC-Q). It includes real-time stock data, dividend information, analyst ratings, financial reports, and a summary of the company's profile as a clinical-stage biopharmaceutical company focused on developing medicines for underserved diseases. The news section details various analyst opinions, company announcements, and updates on their oncology pipeline and clinical trials.
Stryker shares plunge 8.8% after CFO reveals ongoing manufacturing issues.
Stryker Corporation's shares dropped 8.8% after its CFO revealed that a manufacturing problem in its Peripheral Vascular unit, previously thought resolved, is continuing into Q4 2026. This disclosure led to a loss of over $10 billion in market value and initiated an investigation into the company's transparency with investors. The ongoing supply disruptions are impacting sales and new business opportunities, raising concerns about future performance.
Stryker (NYSE: SYK) Scrutinized Amid Disclosure of Persisting Peripheral Vascular Problems -- HBSS
Hagens Berman has launched an investigation into Stryker (NYSE: SYK) following a significant drop in share price after the company's CFO disclosed that a previously reported manufacturing issue in its Peripheral Vascular unit, acquired through Inari Medical, is persisting longer than initially assured. Investors experienced a substantial loss when the CFO revealed that the problem would continue into Q4, contradicting earlier statements that it would be resolved by the end of Q3. The firm is investigating whether Stryker was sufficiently transparent about the issue and whether it violated federal securities laws.
TD Cowen cuts target for Stryker stock from USD 355.00 to USD 298.00
TD Cowen has lowered its price target for Stryker (SYK) stock from $355.00 to $298.00 while maintaining a Hold rating, citing increased seasonality and softer trends in the hip and knee markets. Despite the target cut, Stryker reported strong Q2 2026 revenues of $6.59 billion and adjusted EPS of $3.69, exceeding consensus estimates. The company's future performance will be closely watched as it continues its production recovery following a prior cyber incident.
Stryker to announce third quarter 2026 financial results
Stryker (NYSE: SYK) will host a webcast on Thursday, October 29, 2026, at 4:30 p.m. Eastern time to discuss its third quarter 2026 financial results. An accompanying press release with summary financial information will be issued at 4:05 p.m. Eastern time on the same day. Stryker is a global leader in medical technologies, providing innovative products and services in MedSurg, Neurotechnology, and Orthopaedics.
Stryker to announce third quarter 2026 financial results
Stryker (NYSE: SYK) will host a webcast on Thursday, October 29, 2026, at 4:30 p.m. Eastern time to discuss its third quarter 2026 financial results. An accompanying press release with summary financial information will be issued at approximately 4:05 p.m. Eastern time on the same day. Both the live webcast and the press release will be accessible via Stryker's website.
Stryker to announce third quarter 2026 financial results
Stryker (NYSE: SYK) is set to announce its third quarter 2026 financial results via a webcast on Thursday, October 29, 2026, at 4:30 p.m. Eastern time. An accompanying press release with summary financial information will be issued at 4:05 p.m. ET on the same day. Both the live webcast and an archive will be accessible on Stryker's website.
Analysts Offer Insights on Healthcare Companies: DocGo (DCGO), Nektar Therapeutics (NKTR) and Stryker (SYK)
This article provides an overview of analyst ratings for three healthcare companies: DocGo (DCGO), Nektar Therapeutics (NKTR), and Stryker (SYK). DocGo received a Hold rating from BTIG, with a Moderate Buy consensus. Nektar Therapeutics maintained a Buy rating from BTIG and a Strong Buy consensus, while Stryker received a Buy rating from Stifel Nicolaus and a Strong Buy consensus.
3 AI Healthcare Stocks With At Least 8% Revenue Growth
This article highlights three AI-driven healthcare stocks—Insmed (INSM), Hinge Health (HNGE), and Stryker (SYK)—that demonstrate at least 8% revenue growth. It discusses how these companies are leveraging AI to innovate in areas like protein engineering, digital musculoskeletal care, and hospital technology. The piece emphasizes the importance of AI applications that address significant problems, especially as investment capital becomes more discerning.
CEUX:SYKd Dividend: Does Stryker Corp Pay a Dividend?
Stryker Corp (CEUX:SYKd) does not currently pay a regular dividend, having returned capital to shareholders primarily through buybacks at a rate of -0.3% over the past three years. The article provides a list of alternative high-yield dividend stocks for investors interested in income-generating investments. It also includes an FAQ section explaining common reasons why companies might not pay dividends.
Insiders At Stryker Sold US$582m In Stock, Alluding To Potential Weakness
This article analyzes insider selling at Stryker (NYSE:SYK), where insiders sold US$582 million worth of stock over the past year. Despite the sales, which were primarily through options exercise, the company's market cap remains robust. The analysis suggests that while significant, these sales alone may not indicate an imminent stock price decline but warrant further investigation into the company's valuation and future prospects.
Stifel Maintains Stryker Corp(SYK.US) With Buy Rating, Cuts Target Price to $330
Stifel has reiterated its Buy rating for Stryker Corp (SYK.US) but has lowered its price target to $330. This adjustment in the price target comes while maintaining a positive outlook on the company's stock.
Stryker stock faces analyst cuts as Stifel lowers target
Stifel has lowered its price target for Stryker (SYK) stock to USD 330.00 from USD 360.00, citing a more challenging second half of the year and orthopedic headwinds, despite maintaining a Buy rating. This revision comes as Stryker's stock was trading up slightly at EUR 246.00 at Lang & Schwarz. The analyst adjusted its 2026 organic revenue growth estimate to the lower end of Stryker's guidance and its adjusted EPS estimate to near the lower end of the company's outlook.
FEIG ETF Holdings List — HAN:FEIG
This article provides a detailed list of the ETF holdings for FEIG (Fidelity EUR Corp Bond Research Enhanced PAB UCITS ETF) as of October 2, 2026. It includes the symbol, weight percentage, number of shares, and market value for each holding. Key holdings mentioned include Euro, JCDecaux SE, Pandora A/S, Mastercard Incorporated, and Stryker Corporation.
A successor's appointment could set the CEO's retirement date at AngioDynamics (ANGO). There's another trigger.
AngioDynamics CEO James C. Clemmer announced his intention to retire by November 30, 2026, or upon the appointment of a successor, with the possibility of monthly extensions by mutual agreement. The company recently amended its fiscal 2026 annual report to include updated XBRL tagging and disclosed performance against cash-incentive targets, showing net sales of $320.2 million against a $312 million target and adjusted EBITDA of $18.2 million versus a $10.5 million target. Executive compensation for fiscal 2026 was largely performance-based, with cash incentive payouts at 180% of target for named executive officers.
Carlsmed names new CFO
Carlsmed has appointed Richard Heppenstall, formerly CFO of ZimVie, as its new Chief Financial Officer, replacing Leo Greenstein. Despite Greenstein's departure, analysts expect no significant change in Carlsmed's strategy. The company reaffirmed its full-year sales guidance of $74 million to $78 million, anticipating 50% growth over 2025 sales, driven by surgeon onboarding and new product launches like the Aprevo platform.
Stryker stock gains 1.77 percent as quarterly growth holds
Stryker (SYK) stock gained 1.77% on September 29, 2026, reaching EUR 246.65, after its latest quarterly earnings beat analyst estimates. The company reported an adjusted EPS of USD 3.69 and revenue of USD 6.59 billion, exceeding expectations. Despite a dividend declaration and strong quarterly performance, analyst targets have been slightly lowered, and the stock remains below its 52-week high.
Stryker Agrees to Acquire ZuriMED to Expand Shoulder Repair Portfolio
Stryker has agreed to acquire ZuriMED, which will add ZuriMED's FiberLocker System to Stryker's shoulder portfolio. The FiberLocker System is a soft tissue augmentation technology designed to increase biomechanical strength during rotator cuff repair, addressing a key clinical failure mode. This acquisition will expand Stryker's offerings for shoulder specialists in sports medicine and arthroplasty, though financial terms were not disclosed and the businesses will operate separately until the transaction closes.
NeurAxis appoints Craig Blanchard as chief commercial officer
NeurAxis, Inc. has announced the appointment of Craig Blanchard as its new Chief Commercial Officer. Blanchard will be responsible for overseeing sales and marketing functions, bringing his extensive experience from NICO Corporation, Boston Scientific, and Guidant Corporation. This strategic hire aims to support the company's commercial expansion and an anticipated increase in coverage for its IB-Stim product, an FDA-cleared device for treating functional abdominal pain in patients aged 8 and older.
Form 4 Stryker Corporation For: 28 September By Investing.com
This article announces the filing of a Form 4 for Stryker Corporation (SYK) for September 28, 2026. The Form 4 is a document filed with the U.S. Securities and Exchange Commission (SEC) by company insiders to report changes in their ownership of the company's securities. The article does not provide specific details about the transactions but notes the company's stock symbol and a slight positive change in its price.
GE HealthCare Technologies Inc. (GEHC) Latest Stock News & Headlines
This article provides a compilation of recent news and headlines concerning GE HealthCare Technologies Inc. (GEHC). It covers various topics including dividend announcements, stock performance analysis, market trends in remote cardiac monitoring, and the appointment of new board members. The collected headlines also discuss GEHC's strategic moves like the launch of its CareIntellect AI tool and potential acquisitions.
A 109-share employee stock plan transfer leaves Stryker (SYK) CFO holding 3,661 shares directly.
Stryker's CFO, Preston Wendell Wells, transferred 109 common shares from the Employee Stock Purchase Plan on September 24, 2026, due to a Matrimonial Settlement Agreement. Following this transfer, his direct holdings in Stryker (SYK) are 3,661 shares, with an additional 310 shares held indirectly through a 401(k). This transaction was reported in a Form 4 filing, indicating a neutral impact and sentiment.
Retired Stryker leader Tim Scannell dies at 62
Tim Scannell, a pivotal leader at Stryker for three decades, passed away at 62 after a 10-month battle with glioblastoma. He was instrumental in propelling Stryker into the Fortune 500, leading various divisions before becoming president and COO. Scannell retired in 2021, leaving behind a legacy of significant growth and a reputation as a dedicated teammate.
Is ResMed A Better Way Than Stryker To Own Medical Device Growth?
This article compares ResMed (RMD) and Stryker (SYK) as medical device investment options, noting their similar growth rates over the past three years. While Stryker is a larger company with a higher price-to-earnings ratio, ResMed shows better profitability, lower debt, and faster revenue growth, making it appear more favorable despite Stryker's lower price-to-sales ratio and elevated order backlog. The author concludes that the evidence favors ResMed, unless Stryker's full-year 2026 growth exceeds its own forecasted range.
Johnson & Johnson Unveils 3 Consecutive New Innovations: Ushering Fracture Treatment into the Fully Automatic Mode Era
Johnson & Johnson, through its DePuy Synthes subsidiary, has introduced three new orthopedic trauma products that aim to automate and improve fracture treatment. These innovations include the MAXFRAME AUTOSTRUT Bluetooth version automatic external fixation system, an expanded VOLT plate system with MOSAIC technology for better anatomical fit, and the upcoming VELYS Trauma AI intraoperative AI system. These products represent a shift towards automated execution, improved implantation, and enhanced guidance in fracture care, addressing the limitations of manual methods and potentially transforming the business model from one-time sales to subscription-based services.
Why Stryker (SYK) Is Back In The Spotlight
Stryker (SYK) is gaining renewed attention after introducing new Foot & Ankle technologies at a recent orthopedic meeting. Despite a recent share price pullback, analysts view the stock as undervalued by approximately 12%, with a fair value estimated around $311. The article highlights Stryker's position as a high-quality medtech leader driven by an aging population, while also acknowledging potential risks such as tightening hospital capital spending or acquisition integration challenges.
27,714 Stryker Corporation $SYK Shares Sold by Engineers Gate Manager LP
Engineers Gate Manager LP significantly reduced its stake in Stryker Corporation by selling 27,714 shares, cutting its holdings by 96.1%. Despite this, institutional investors and hedge funds still own a substantial 77.09% of SYK. Stryker, trading near its 12-month low, maintains a "Moderate Buy" consensus from analysts with an average price target of $374.42, driven by strong earnings and dividend performance.
How Investors Are Reacting To Stryker (SYK) Ankle Surgery Planning Launch
Stryker (SYK) recently unveiled new Foot & Ankle technologies, including the Prophecy Surgical Planning for its Incompass Total Ankle System, which integrates preoperative data into product development and surgical workflows. This innovation is expected to reinforce Stryker's strategy of driving growth through data-guided implants and complex procedures, despite current challenges like manufacturing disruptions and legal scrutiny. Analysts project significant revenue and earnings growth for Stryker by 2029, with some estimates suggesting a potential 35% upside to its current stock price.
STERIS stock last at USD 208.44, down 0.16 percent in New York trading
STERIS stock closed at USD 208.44, down 0.16 percent, underperforming the S&P 500 which gained 0.53 percent. The company recently announced a USD 600 million investment in a North Carolina manufacturing and distribution campus, while Argus lowered its price target for STERIS to USD 240.00. The stock lagged behind healthcare peers like Abbott Laboratories and Stryker during the session.
Stryker stock trades at USD 270.92, down 0.91 percent in New York trading
Stryker stock closed at USD 270.92, down 0.91 percent, on September 25, 2026, lagging the DAX. TD Cowen cut its target to USD 298 from USD 355 due to margin concerns, maintaining a Hold rating. The company's next shareholder event is the ex-dividend date on September 30, 2026, for a USD 0.88 distribution.
Zimmer Biomet stock trades at USD 91.57, up 2.10 percent in New York trading
Zimmer Biomet stock traded at USD 91.57, up 2.10 percent in New York trading, outperforming the SPY's 0.46 percent gain. The stock opened at USD 89.53 and reached a session high of USD 91.84, with trading volume at 474,121 shares. Analyst estimates from Zacks support the move, with 10 analysts revising fiscal 2026 earnings estimates higher and the company also announced a quarterly dividend of USD 0.24 per share with a record date of September 30, 2026.
Form 4 Stryker Corporation For: 25 September By Investing.com
This article announces the filing of Form 4 for Stryker Corporation on September 25. It is a brief, procedural notice from Investing.com, providing no further details about the Form 4 content.
Form 4 Stryker Corporation For: 25 September By Investing.com
This article reports on a Form 4 filing for Stryker Corporation (SYK) for the 25th of September. It notes the stock's current performance with a -1.34% change. The content primarily serves as a placeholder for the filing details, which are not explicitly provided in the snippet, and includes various financial market data and related news.
Envestnet Asset Management Inc. Purchases 70,634 Shares of Stryker Corporation $SYK
Envestnet Asset Management Inc. increased its holdings in Stryker Corporation by 12.2% in the second quarter, purchasing 70,634 additional shares to own a total of 650,461 shares valued at approximately $204.8 million. Institutional investors now hold 77.09% of Stryker's stock, while company insiders have sold shares worth about $118.2 million in the last 90 days. Analysts maintain a "Moderate Buy" consensus rating for Stryker with an average price target of $374.42, following strong quarterly results where earnings and revenue exceeded expectations.
Stryker Corp. stock slips 1.2 percent ahead of the open
Stryker Corp. (US8636671013) stock declined by 1.2 percent on September 24, 2026, closing at USD 270.21 on the NYSE, underperforming the S&P 500. The company also announced a USD 0.88 quarterly dividend for shareholders of record on September 30, 2026, with payment scheduled for October 30, 2026. The stock's 52-week range is USD 267.00 to USD 392.55, and the decline occurred amidst elevated bond yields and oil prices.
How Lingo Partnership Will Impact Abbott Stock (ABT)
Abbott Laboratories recently announced a partnership with Berry Street, integrating its Lingo glucose monitor with virtual nutrition coaching, alongside the expansion of its Volt Pulsed Field Ablation System for cardiac procedures. This collaboration, especially with Lingo, aims to extend glucose tracking beyond traditional diabetes care, influencing Abbott's long-term investment narrative by pushing into everyday health use cases, though near-term earnings risks persist due to legal and regulatory issues in its Nutrition arm. While the partnership supports Abbott's operational goals and potential revenue growth, its impact on the company's financial forecasts and overall fair value remains a subject of varied analyst opinions.
Stryker Corporation (SYK) Options Chain - Yahoo Finance
The article provides the options chain for Stryker Corporation (SYK), including a brief summary of its stock performance, a recent dividend announcement, and real-time pricing information. It details call and put options, though none are currently listed as "In The Money." The data is delayed by 15 minutes.
Stryker faces investigation after CEO reveals ongoing manufacturing issues, stock drops 8.8%.
Stryker Corp is under investigation by Pomerantz LLP for potential securities fraud. This follows the CEO's disclosure of unresolved manufacturing problems in its peripheral vascular business, which led to an almost 9% stock drop on September 8, 2026. The issue, initially expected to be resolved by Q3 2026, is now anticipated to continue into Q4.
